Recurrent Indolent Non-Hodgkin Lymphoma
3 clinical trials · Condition
◉ Watch Recurrent Indolent Non-Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
Track Recurrent Indolent Non-Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.